Biomarker · Cell-surface target
CD30 (TNFRSF8)
Activation antigen expressed on Hodgkin/Reed-Sternberg and anaplastic large-cell lymphoma cells, detected by immunohistochemistry; the target antigen of CD30-directed antibody-drug conjugates and a diagnostic marker.
CI-BIO-00000044TNFRSF8graph →NCIt C129257
Also calledCD30 · CD30-positive · TNFRSF8 · Ki-1 antigen
Derived
Associated cancers (0)
Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.
Data not yet available
Derived
Drugs with predictive evidence (0)
Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.
Data not yet available
Curated evidence
Predictive evidence items (0)
ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.
Data not yet available
Regulatory
Approvals mentioning the linked drugs (1)
Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.
- Source
- openFDA — Drugs@FDA applications and drug labels (SPL)
- Dataset
- Drugs@FDA via openFDA
- Version
- drugsfda-2026-09-11
- Retrieved
- Sep 14, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- CC0 1.0 Universal (public domain; https://open.fda.gov/license/)
- Run
- ING-OPENFDA-20260914-000001
Clinical trials
Active trials (0)
Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 0 recruiting · 0 active phase 3 · 0 in any status. Most recently updated first, 50 per page.
Data not yet available
Literature
Linked publications (0)
Data not yet available